The sevenfact market research report is one of a series of new reports that provides sevenfact market statistics, including sevenfact industry global market size, regional shares, competitors with a sevenfact market share, detailed sevenfact market segments, market trends and opportunities, and any further data you may need to thrive in the sevenfact industry. This sevenfact market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growing adoption of prophylaxis treatment, increasing in number of hemophilia patients, increasing prevalence of blood disorders, rising government healthcare spending, and rising adoption of personalized medicine. Major trends in the forecast period include technological advancements, targeted therapies, personalized medicine, integration with genetic therapies, and integration of digital health technologies.
The growing prevalence of blood disorders is expected to fuel the growth of the Sevenfact market in the coming years. Blood disorders involve conditions that affect the function or components of blood, such as red blood cells, white blood cells, platelets, or plasma. The rise in blood disorders can be attributed to factors such as an aging population, genetic factors, chronic diseases, and infections or inflammation. Sevenfact aids in the management of blood disorders by supporting effective blood clotting in patients with hemophilia A or B who have inhibitors, helping control bleeding episodes and reducing the risk of severe complications. For example, the Centers for Disease Control and Prevention reported in April 2024 that there were 2.8 million physician office visits for anemia as the primary diagnosis, with 6,021 deaths related to the condition, resulting in a mortality rate of 1.8 deaths per 100,000 people. As a result, the increasing prevalence of blood disorders is contributing to the growth of the Sevenfact market.
The expansion of government healthcare spending is also anticipated to drive the growth of the Sevenfact market. Government healthcare spending refers to the allocation of public funds to support healthcare services, infrastructure, and programs for citizens. This rise in spending is driven by an aging population, the increasing prevalence of chronic diseases, advances in medical technology, and the need to enhance healthcare infrastructure. Sevenfact can help manage government healthcare expenses by offering an affordable treatment for hemophilia patients with inhibitors, potentially reducing long-term costs associated with frequent hospitalizations and emergency care while improving patient outcomes. For example, according to the Canadian Institute for Health Information, in November 2023, total healthcare spending in Canada was projected to reach $344 billion, marking a modest 2.8% increase from the previous year. Consequently, the rise in government healthcare spending is influencing the growth of the Sevenfact market.
The growing adoption of personalized medicine is another factor expected to propel the Sevenfact market. Personalized medicine involves tailoring treatments based on an individual's genetic makeup, lifestyle, and environmental factors to achieve more effective outcomes. Several factors, including advancements in genomic research, enhanced diagnostic tools, and the increasing demand for targeted therapies, are driving the adoption of personalized medicine. Sevenfact supports this trend by enabling personalized care for hemophilia patients, where clinicians can adjust the dosage according to individual needs to prevent bleeding and improve the patient's quality of life. For example, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of personalized medicine is contributing to the expansion of the Sevenfact market.
The key company operating in the sevenfact market is HEMA Biologics Inc.
North America was the largest region in the sevenfact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sevenfact report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sevenfact market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Sevenfact is a recombinant coagulation factor VIIa (eptacog beta) used to treat and control bleeding episodes in patients with hemophilia A or B who have inhibitors. It works by promoting blood clot formation, helping to manage bleeding in affected individuals.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Sevenfact include hemophilia A and hemophilia B. Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, resulting in difficulty with blood clotting and frequent bleeding episodes. Sevenfact is distributed through hospital pharmacies and specialty pharmacies, with end-use settings that include hospitals, clinics, ambulatory care, and home care.
The sevenfact market consists of sales of sevenfact injections, sevenfact lyophilized powder, and sevenfact prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing adoption of prophylaxis treatment, increasing in number of hemophilia patients, increasing prevalence of blood disorders, rising government healthcare spending, and rising adoption of personalized medicine. Major trends in the forecast period include technological advancements, targeted therapies, personalized medicine, integration with genetic therapies, and integration of digital health technologies.
The growing prevalence of blood disorders is expected to fuel the growth of the Sevenfact market in the coming years. Blood disorders involve conditions that affect the function or components of blood, such as red blood cells, white blood cells, platelets, or plasma. The rise in blood disorders can be attributed to factors such as an aging population, genetic factors, chronic diseases, and infections or inflammation. Sevenfact aids in the management of blood disorders by supporting effective blood clotting in patients with hemophilia A or B who have inhibitors, helping control bleeding episodes and reducing the risk of severe complications. For example, the Centers for Disease Control and Prevention reported in April 2024 that there were 2.8 million physician office visits for anemia as the primary diagnosis, with 6,021 deaths related to the condition, resulting in a mortality rate of 1.8 deaths per 100,000 people. As a result, the increasing prevalence of blood disorders is contributing to the growth of the Sevenfact market.
The expansion of government healthcare spending is also anticipated to drive the growth of the Sevenfact market. Government healthcare spending refers to the allocation of public funds to support healthcare services, infrastructure, and programs for citizens. This rise in spending is driven by an aging population, the increasing prevalence of chronic diseases, advances in medical technology, and the need to enhance healthcare infrastructure. Sevenfact can help manage government healthcare expenses by offering an affordable treatment for hemophilia patients with inhibitors, potentially reducing long-term costs associated with frequent hospitalizations and emergency care while improving patient outcomes. For example, according to the Canadian Institute for Health Information, in November 2023, total healthcare spending in Canada was projected to reach $344 billion, marking a modest 2.8% increase from the previous year. Consequently, the rise in government healthcare spending is influencing the growth of the Sevenfact market.
The growing adoption of personalized medicine is another factor expected to propel the Sevenfact market. Personalized medicine involves tailoring treatments based on an individual's genetic makeup, lifestyle, and environmental factors to achieve more effective outcomes. Several factors, including advancements in genomic research, enhanced diagnostic tools, and the increasing demand for targeted therapies, are driving the adoption of personalized medicine. Sevenfact supports this trend by enabling personalized care for hemophilia patients, where clinicians can adjust the dosage according to individual needs to prevent bleeding and improve the patient's quality of life. For example, the Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of personalized medicine is contributing to the expansion of the Sevenfact market.
The key company operating in the sevenfact market is HEMA Biologics Inc.
North America was the largest region in the sevenfact market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sevenfact report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the sevenfact market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Sevenfact is a recombinant coagulation factor VIIa (eptacog beta) used to treat and control bleeding episodes in patients with hemophilia A or B who have inhibitors. It works by promoting blood clot formation, helping to manage bleeding in affected individuals.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Sevenfact include hemophilia A and hemophilia B. Hemophilia A is a genetic bleeding disorder caused by a deficiency of clotting factor VIII, resulting in difficulty with blood clotting and frequent bleeding episodes. Sevenfact is distributed through hospital pharmacies and specialty pharmacies, with end-use settings that include hospitals, clinics, ambulatory care, and home care.
The sevenfact market consists of sales of sevenfact injections, sevenfact lyophilized powder, and sevenfact prefilled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Sevenfact Market Characteristics4. Sevenfact Market Trends And Strategies5. Sevenfact Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Sevenfact Pricing Analysis & Forecasts30. Global Sevenfact Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Sevenfact Market32. Recent Developments In The Sevenfact Market
3. Sevenfact Market Biologic Drug Characteristics
6. Global Sevenfact Growth Analysis And Strategic Analysis Framework
8. Sevenfact Market Segmentation
9. Global Sevenfact Epidemiology Of Clinical Indications
10. Sevenfact Market Regional And Country Analysis
11. Asia-Pacific Sevenfact Market
12. China Sevenfact Market
13. India Sevenfact Market
14. Japan Sevenfact Market
15. Australia Sevenfact Market
16. South Korea Sevenfact Market
17. Western Europe Sevenfact Market
18. UK Sevenfact Market
19. Germany Sevenfact Market
20. France Sevenfact Market
21. Eastern Europe Sevenfact Market
22. North America Sevenfact Market
23. USA Sevenfact Market
24. Canada Sevenfact Market
25. South America Sevenfact Market
26. Middle East Sevenfact Market
27. Africa Sevenfact Market
28. Sevenfact Market Competitive Landscape And Company Profiles
29. Global Sevenfact Market Pipeline Analysis
33. Sevenfact Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Sevenfact Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on sevenfact market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sevenfact ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sevenfact market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Hemophilia A; Hemophilia B2) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Profiled: HEMA Biologics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- HEMA Biologics Inc.
